Literature DB >> 32829460

Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia.

Ramona Wullenkord1, Christian Reicherts1, Jan-Henrik Mikesch1, Julia Marx1, Klaus Wethmar1, Jörn Albring1, Simon Call1, Georg Lenz1, Matthias Stelljes2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32829460      PMCID： PMC7817557          DOI： 10.1007/s00277-020-04227-8

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  11 in total

1.  Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.

Authors:  Hagop Kantarjian; Anthony Stein; Nicola Gökbuget; Adele K Fielding; Andre C Schuh; Josep-Maria Ribera; Andrew Wei; Hervé Dombret; Robin Foà; Renato Bassan; Önder Arslan; Miguel A Sanz; Julie Bergeron; Fatih Demirkan; Ewa Lech-Maranda; Alessandro Rambaldi; Xavier Thomas; Heinz-August Horst; Monika Brüggemann; Wolfram Klapper; Brent L Wood; Alex Fleishman; Dirk Nagorsen; Christopher Holland; Zachary Zimmerman; Max S Topp
Journal:  N Engl J Med       Date:  2017-03-02       Impact factor: 91.245

Review 2.  Treatment of older patients with acute lymphoblastic leukemia.

Authors:  Nicola Gökbuget
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 3.  CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.

Authors:  Jae H Park; Mark B Geyer; Renier J Brentjens
Journal:  Blood       Date:  2016-05-20       Impact factor: 22.113

4.  Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007.

Authors:  Graça M Dores; Susan S Devesa; Rochelle E Curtis; Martha S Linet; Lindsay M Morton
Journal:  Blood       Date:  2011-11-15       Impact factor: 22.113

5.  Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

Authors:  Hagop M Kantarjian; Daniel J DeAngelo; Matthias Stelljes; Giovanni Martinelli; Michaela Liedtke; Wendy Stock; Nicola Gökbuget; Susan O'Brien; Kongming Wang; Tao Wang; M Luisa Paccagnella; Barbara Sleight; Erik Vandendries; Anjali S Advani
Journal:  N Engl J Med       Date:  2016-06-12       Impact factor: 91.245

6.  Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.

Authors:  Jae H Park; Isabelle Rivière; Mithat Gonen; Xiuyan Wang; Brigitte Sénéchal; Kevin J Curran; Craig Sauter; Yongzeng Wang; Bianca Santomasso; Elena Mead; Mikhail Roshal; Peter Maslak; Marco Davila; Renier J Brentjens; Michel Sadelain
Journal:  N Engl J Med       Date:  2018-02-01       Impact factor: 91.245

7.  Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.

Authors:  Elias J Jabbour; Daniel J DeAngelo; Matthias Stelljes; Wendy Stock; Michaela Liedtke; Nicola Gökbuget; Susan O'Brien; Tao Wang; M Luisa Paccagnella; Barbara Sleight; Erik Vandendries; Anjali S Advani; Hagop M Kantarjian
Journal:  Cancer       Date:  2018-01-30       Impact factor: 6.860

8.  New Approaches to the Management of Adult Acute Lymphoblastic Leukemia.

Authors:  Renato Bassan; Jean-Pierre Bourquin; Daniel J DeAngelo; Sabina Chiaretti
Journal:  J Clin Oncol       Date:  2018-09-21       Impact factor: 44.544

9.  Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.

Authors:  Loretta J Nastoupil; Michael D Jain; Lei Feng; Jay Y Spiegel; Armin Ghobadi; Yi Lin; Saurabh Dahiya; Matthew Lunning; Lazaros Lekakis; Patrick Reagan; Olalekan Oluwole; Joseph McGuirk; Abhinav Deol; Alison R Sehgal; Andre Goy; Brian T Hill; Khoan Vu; Charalambos Andreadis; Javier Munoz; Jason Westin; Julio C Chavez; Amanda Cashen; N Nora Bennani; Aaron P Rapoport; Julie M Vose; David B Miklos; Sattva S Neelapu; Frederick L Locke
Journal:  J Clin Oncol       Date:  2020-05-13       Impact factor: 50.717

Review 10.  Management of older adults with acute lymphoblastic leukemia: challenges & current approaches.

Authors:  Yazeed Sawalha; Anjali S Advani
Journal:  Int J Hematol Oncol       Date:  2018-04-10
View more
  1 in total

Review 1.  Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies.

Authors:  Xinyi Xiao; Yazhuo Wang; Zhengbang Zou; Yufei Yang; Xinyu Wang; Xin Xin; Sanfang Tu; Yuhua Li
Journal:  Front Immunol       Date:  2022-08-23       Impact factor: 8.786
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.